Mobile Health Intervention Fails to Cut Hospitalizations in Older Atrial Fibrillation Patients

A large European trial designed to demonstrate that a smartphone-supported, integrated care system could keep older, multimorbid patients with atrial fibrillation out of the hospital has delivered a sobering and unexpectedly instructive result: the digital intervention made no measurable difference. The AFFIRMO trial, a cluster-randomised study conducted across six European countries, found that an mHealth platform built around the Atrial Fibrillation Better Care (ABC) pathway and enriched with comprehensive geriatric assessment did not reduce unplanned all-cause hospitalisations compared with usual care. The findings, published in The Lancet Regional Health – Europe, offer one of the clearest illustrations yet that digital health tools cannot improve outcomes when the underlying care is already close to optimal.

Atrial fibrillation, the most common sustained cardiac arrhythmia, becomes increasingly prevalent with age, and contemporary patients are typically older, frailer and burdened by multiple chronic conditions. This complexity raises the risk not only of stroke and bleeding but also of non-cardiovascular events and hospital admissions, driving substantial healthcare costs. The ABC pathway was proposed as a structured framework to streamline integrated management: ‘A’ for anticoagulation and stroke risk avoidance, ‘B’ for better symptom control, and ‘C’ for cardiovascular and comorbidity optimisation. Observational studies repeatedly linked adherence to the pathway with lower mortality, stroke and bleeding, and two cluster-randomised trials in Asia—one app-based in largely urban China and one delivered by village doctors with telehealth support in rural settings—had shown that ABC implementation improved guideline adherence and reduced adverse outcomes, including hospitalisations.

What remained unknown was whether the same approach would work in European healthcare systems, specifically among patients aged 65 or older with atrial fibrillation and at least one additional chronic condition. The AFFIRMO investigators, led by Gregory Y.H. Lip and Marco Proietti, designed a multicentre, open-label cluster-randomised trial across Bulgaria, Denmark, Italy, Romania, Serbia and Spain. Clinical centres, not individual patients, were randomised to deliver either the integrated mHealth intervention—dubbed the iABC system—or routine guideline-based care. The intervention combined a patient-facing mobile application with a clinician dashboard, and every intervention patient underwent a comprehensive geriatric assessment at baseline to identify functional domains requiring management.

The AFFIRMO Mobile App collected daily data on vital signs, oral anticoagulant adherence, arrhythmia symptoms and chronic conditions, while dispensing tailored health tips for lifestyle and comorbidity management. Each patient also completed the Patient Health Engagement scale at activation, which determined the level of personalised educational material they received about atrial fibrillation. On the clinical side, the AFFIRMO Clinician Dashboard summarised app usage and patient-entered data, organised by the three ABC pillars, to inform follow-up consultations. Between April 2024 and January 2025, the trial enrolled 1,260 patients, with 634 assigned to the iABC system and 626 to usual care. Follow-up visits occurred at 3, 6 and 12 months, and the primary endpoint was unplanned all-cause hospitalisation during one year of follow-up, adjudicated by a blinded event validation committee.

The enrolled population reflected the modern reality of atrial fibrillation care: a mean age of 73 to 74 years, a median CHA2DS2-VASc stroke risk score of 4, and a heavy burden of comorbidity. Roughly 40 percent had more than two chronic conditions, hypertension treated with multiple drugs was nearly universal, and polypharmacy affected 72 percent of participants. Yet the trial’s most consequential baseline finding was how well these patients were already being treated: 97.3 percent were on oral anticoagulation, overwhelmingly direct oral anticoagulants, and use of beta-blockers, anti-arrhythmic drugs and other guideline-directed therapies was uniformly high. Comprehensive geriatric assessment in the intervention arm revealed a largely functionally preserved cohort, with 95.7 percent showing normal cognition, 83.9 percent normal nutritional status, and only about 20 percent reporting meaningful mobility impairment.

After a mean follow-up of 367 days, unplanned all-cause hospitalisation occurred in 17.1 percent of the iABC group versus 18.2 percent of the usual care group—an adjusted odds ratio of 0.95 with a 95 percent confidence interval of 0.61 to 1.49 and a p-value of 0.84. Sensitivity analyses, including a Cox proportional hazards model and a composite endpoint of hospitalisation or death, told the same neutral story. No secondary endpoint differed between groups: all-cause death, any hospitalisation, stroke or cardiovascular death, heart failure events, renal worsening, and major bleeding, which occurred in only 0.7 percent of all participants, were statistically indistinguishable across arms. Subgroup analyses by age, sex, comorbidity count, medication number and country revealed no hidden pockets of benefit.

The investigators attribute the null result to a convergence of factors, each instructive in its own right. First, the trial’s power calculation assumed a 30 percent event rate in usual care and a 25 percent relative reduction with the intervention; instead, usual care produced only an 18.2 percent hospitalisation rate. With such low residual risk, several thousand patients would have been required to detect a statistically significant difference. Second, the baseline quality of care starkly contrasts with the prior Asian trials: in the mAFA trial, oral anticoagulant use at baseline was just 48.4 percent in usual care, and in the MIRACLE-AF rural trial it was around 11 percent. In those settings, the ABC intervention raised anticoagulation dramatically and reduced hospitalisations. In AFFIRMO, with anticoagulation already at 97 percent, there was simply little therapeutic ground left for a digital nudge to reclaim.

Third, and perhaps most telling, patients barely used the app. The median percentage of days on which patients accessed the AFFIRMO Mobile App was 15.1 percent, and 68.5 percent of patients fell into the lowest tertile of use, opening the app on only about one-third or fewer of their study days. The authors point to well-documented implementation barriers—digital literacy in an older population, workflow incompatibility, and difficulty integrating digital tools into complex health systems. Clinical decision support, they note, only works when it is actually used; in the O’CAFÉ trial, modest overall effects sharpened into significant anticoagulation improvements only among clinicians who actively engaged with the tool. Because the mobile app is half of the iABC system, its companion physician dashboard inheriting the consequences of underuse, suboptimal engagement directly undermined the intervention’s theoretical effectiveness.

Fourth, comprehensive geriatric assessment itself ran into a ceiling effect. Although more than half of the intervention patients showed some degree of frailty on the FRAIL scale, most were robust on objective measures of daily functioning, cognition, nutrition and mood. In such high-functioning individuals, geriatric assessment may serve a descriptive rather than an interventional role, and prior evidence suggests little clinical benefit from CGA in robust patients. The trial’s design assumed more functional impairment than it found, constraining the scope for assessment-driven management changes. Not all signals were negative, however: patients in the intervention arm showed numerically higher uptake of several guideline-directed treatments at the final visit, including mineralocorticoid receptor antagonists, SGLT2 inhibitors and anti-arrhythmic drugs, and a significantly lower rate of uncontrolled systolic blood pressure at 12 months (1.5 versus 4.0 percent), hinting at secondary improvements in care quality even without hard outcome benefits.

The broader lesson echoes the recent STEEER-AF trial, in which an electronic education programme for clinicians also yielded only marginal improvements because guideline adherence was already high in both arms. The authors emphasise that the results do not disqualify integrated care or the ABC pathway, which remains embedded in European Society of Cardiology guidance through the 2020 ABC framework and the 2024 AF-CARE scheme. Rather, they argue, integrated care interventions and digital health tools must be targeted at settings with genuine unmet clinical need—populations with low baseline guideline adherence, higher residual risk, or greater functional impairment. Future studies may also need easier-to-use apps, co-designed with older patients, and more selected populations in which the theoretical benefit of holistic optimisation has room to translate into fewer hospitalisations. For now, AFFIRMO stands as a rigorous, well-conducted demonstration that in medicine, as in engineering, the marginal return on optimisation shrinks as the system approaches its ceiling—and that digital tools, however elegantly engineered, cannot multiply benefit that better baseline care has already claimed.

Subject of Research: A cluster-randomised trial of mHealth-based integrated care and comprehensive geriatric assessment in older multimorbid patients with atrial fibrillation.

Article Title: Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial

Article References: Lip, G. Y., Proietti, M., Ainsworth, J., Dan, G.-A., Frost, L., Graffigna, G., Lane, D. A., Lucci, D., Fabbri, G., Marin, F., O'Flaherty, M., Petrovic, M., Potpara, T. S., Proietti, R., Sanaullah, A., Tokmakova, M., Vetrano, D. L., Johnsen, S. P., Maggioni, A. P., … Tokmakova, M. (2026). Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial. The Lancet Regional Health – Europe, 70, Article 101832. https://doi.org/10.1016/j.lanepe.2026.101832

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101832

Keywords: atrial fibrillation, AFFIRMO trial, mHealth, integrated care, ABC pathway, comprehensive geriatric assessment, multimorbidity, cluster-randomised trial, unplanned hospitalisation, digital health, older adults, guideline adherence